deltatrials
Completed PHASE3 NCT01099436

Neo-Adjuvant Chemotherapy (TAC) With or Without Zoledronic Acid in Treating HER2-negative Breast Cancer Patients

A Phase III Randomized Trial With NEOadjuvant Chemotherapy (TAC) With or Without ZOledronic Acid for Patients With HER2- Negative Large Resectable or Locally Advanced Breast Cancer(NEO-ZOTAC)

Sponsor: Amgen

Conditions Breast Cancer
Interventions cyclophosphamide docetaxel doxorubicin hydrochloride neoadjuvant therapy zoledronic acid
Updated 6 times since 2017 Last updated: Jan 16, 2020 Started: Apr 30, 2010 Primary completion: Apr 30, 2012 Completion: Sep 30, 2013

Listed as NCT01099436, this PHASE3 trial focuses on Breast Cancer and remains completed. Sponsored by Amgen, it has been updated 6 times since 2010, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  4. Feb 2020 — Jan 2021 [monthly]

    Completed PHASE3

  5. Jun 2018 — Feb 2020 [monthly]

    Completed PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Apr 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Amgen
  • Borstkanker Onderzoek Groep
  • Dutch Cancer Society
  • Novartis
  • Sanofi
Data source: Borstkanker Onderzoek Groep

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Leiden, Netherlands